BRIEF published on 02/24/2026 at 07:35, 9 days 8 hours ago Nicox Reveals Positive Phase 3 Results for NCX 470 at AGS Meeting Glaucoma Phase 3 Study NCX 470 Intraocular Pressure Therapeutic Profile
PRESS RELEASE published on 02/24/2026 at 07:30, 9 days 8 hours ago Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting Nicox announces positive NCX 470 Phase 3 data on intraocular pressure lowering efficacy at 2026 American Glaucoma Society Annual Meeting Nicox NCX 470 Phase 3 Data Intraocular Pressure Glaucoma Society
BRIEF published on 02/16/2026 at 07:35, 17 days 8 hours ago Nicox is preparing an NDA submission for NCX 470 following a positive FDA opinion FDA Glaucoma NDA Nicox NCX 470
BRIEF published on 02/16/2026 at 07:35, 17 days 8 hours ago Nicox Receives Positive Feedback from FDA for NCX 470 NDA FDA Nicox Glaucoma Treatment NCX 470 NDA Submission
PRESS RELEASE published on 02/16/2026 at 07:30, 17 days 8 hours ago Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 Nicox receives positive feedback from pre-NDA meeting with U.S. FDA for NCX 470, on track for NDA submission in summer 2026. NCX 470 lowers intraocular pressure in glaucoma patients FDA Nicox NCX 470 Intraocular Pressure Pre-NDA
BRIEF published on 02/12/2026 at 07:35, 21 days 8 hours ago Nicox maintains its PEA-PME status for 2026 PEA-PME Euronext Growth Paris Investment Ophthalmology Nicox
BRIEF published on 02/10/2026 at 07:35, 23 days 8 hours ago Nicox to Present Key Data at AGS Annual Meeting 2026 Clinical Trials Glaucoma Nicox NCX 470 AGS 2026
PRESS RELEASE published on 02/10/2026 at 07:30, 23 days 8 hours ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
BRIEF published on 01/20/2026 at 07:35, 1 month 16 days ago Nicox announces its participation in several congresses in 2026 Glaucoma Ophthalmology Nicox NCX 470 Congress 2026
BRIEF published on 01/20/2026 at 07:35, 1 month 16 days ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
Published on 03/05/2026 at 14:00, 1 hour 37 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 1 hour 37 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 1 hour 37 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 1 hour 57 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 2 hours 7 minutes ago Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 15:06, 31 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 03/05/2026 at 15:05, 32 minutes ago Beyond Alliance: Leading Companies will direct $100m to Cut Superpollutants
Published on 03/04/2026 at 23:50, 15 hours 47 minutes ago Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 21 hours 37 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 21 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
